The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsAnti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.The interconnectedness of cancer cell signaling.The War on Cancer rages on.Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.Intratumor heterogeneity and its impact on drug distribution and sensitivity.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions.High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.
P2860
Q24628746-81642CA8-3EC9-48C2-ADB5-1B3FA4971354Q26746067-D87FCF4F-4E33-429A-A5DB-B5F014289E88Q26796955-59F3FFF4-4FB9-4FC9-B1D9-17CD1D1C7858Q30828511-3C872FCE-45F7-40B2-A07E-656274D2A818Q35476298-37DA34A8-2610-41BF-8422-67F02B2231CFQ35669733-1776F3DE-25B1-4047-9578-56613A054B6FQ37478602-7AA38825-1A64-41DB-B896-B5D6201DBB7DQ37522770-BF43EBD5-B960-4123-A6C8-1A05B024F79AQ37587264-3F44D441-D14D-4293-B6CC-4C8B07AE331AQ38150356-488FD456-5099-4BBF-8896-C030DCFAF8B1Q38211694-07EB5E4E-4307-416B-A709-E1E40FDF08CFQ38631373-8E5B0263-2734-4066-A2C3-845EB69A7DA9Q47804226-9716B279-A68E-4713-A808-68CE7B75ECF5Q48182234-B25B115B-ABA9-4E88-8289-E99F46C53E58Q52882763-C83DEEF4-82E4-4D85-9764-9CB89916BDEF
P2860
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The effects of vandetanib on p ...... del of human ovarian carcinoma
@ast
The effects of vandetanib on p ...... del of human ovarian carcinoma
@en
The effects of vandetanib on p ...... el of human ovarian carcinoma.
@nl
type
label
The effects of vandetanib on p ...... del of human ovarian carcinoma
@ast
The effects of vandetanib on p ...... del of human ovarian carcinoma
@en
The effects of vandetanib on p ...... el of human ovarian carcinoma.
@nl
prefLabel
The effects of vandetanib on p ...... del of human ovarian carcinoma
@ast
The effects of vandetanib on p ...... del of human ovarian carcinoma
@en
The effects of vandetanib on p ...... el of human ovarian carcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
The effects of vandetanib on p ...... del of human ovarian carcinoma
@en
P2093
Alexander Berndt
Hartwig Kosmehl
Marta Cesca
Petra Richter
Valentina Scarlato
P2860
P304
P356
10.1593/NEO.09866
P577
2009-11-01T00:00:00Z